Overview
- 62 inspections across 58 sites are on record.
- 151 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2018-12-14.
At a glance
Inspections
62
Sites
58
Observations
151
Career since
May 2010
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Lonza Guangzhou Pharmaceutical Ltd. | 14 Dec 2018 | Human Drugs | |
| Zhejiang Apeloa Kangyu Pharmaceutical Co., Ltd. | 7 Dec 2018 | Human Drugs | On file |
| Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory | 30 Nov 2018 | Human Drugs | On file |
| Catalent CTS, LLC | 23 Oct 2018 | Human Drugs | On file |
| Lupin Limited | 31 Aug 2018 | Human Drugs | On file |
Sites inspected
Lonza Guangzhou Pharmaceutical Ltd.Guangzhou, China1 insp.
Zhejiang Apeloa Kangyu Pharmaceutical Co., Ltd.Jinhua, China1 insp.
Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical FactoryXinchang, China1 insp.
Catalent CTS, LLCKansas City, United States1 insp.
Lupin LimitedTarapur, Thane, India1 insp.
Co-investigators
Investigators who share inspections with this person.
Rebecca E Dombrowski6 shared
Jeffrey D Meng5 shared
Meisha R Waters4 shared
Meisha R Sampson4 shared
Emily J Orban4 shared
Ross J Grigsby2 shared
Azza Talaat2 shared
Jogy George2 shared
Richard A Lyght2 shared
Sandra A Hughes2 shared
Full investigator report
Get the verbatim findings behind Andrew J Idzior's 151 observations
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site